We recommend that you always use the latest version of your browser.

Neuroscience South

Research on the nervous system and diseases of the nervous system

nevroforsk sør.jpg

Genetics of amyotrophic lateral sclerosis (ALS) in Norway

Departs from Telemark

We contribute to patient recruitment/data collection.

Multicenter study that will map the genetic profile in ALS patients

More information (external website)​

: Local contact: Unn Ljøstad

NO-A LS Extension Study

Departs from Haukeland/UiB

We contribute to patient recruitment/data collection.

Evaluate safety and make Nicotinamide/pterostilbene supplementation available for compassionate use for ALS patients from Agder who have completed the NO-ALS study.

More information (external website)

: Local contacts: Unn Ljøstad and Kristine Forselv

NoCVT: Incidence, diagnosis, and treatment of cerebral venous thrombosis in Norway

: Departs from Ahus

We will contribute to patient recruitment/data collection.

: Multi-center study

More information (external website)

: Local contact: Unn Ljøstad

TWIST: Tenecteplase in Wake-up Ischemic Stroke Trial

: Departs from the university hospital in Northern Norway.

A multinational and cross-regional project

: A PhD candidate from SSHF

  1. Can tenecteplase given within 4.5 hours after awakening improve functional level at 6 months? (randomized-controlled study of thrombolytic treatment with tenecteplase in patients with acute stroke that occurred before awakening)
  2. : Can findings on CT scans identify patients who would benefit particularly from this treatment?

: PhD Candidate: Mary-Helen Søyland

: Supervisor: Arnstein Tveiten ++

: Funding: The Research Council of Norway, The Norwegian Association for Public Health, North Norway Regional Health Authority and ?

More information (external website)

 

COVITA

: Departs from Telemark

We contribute with patient recruitment/data collection.

Monitoring the development of SARS-CoV-2 IgG antibody levels over time to learn more about immunity and mapping of long-term health problems.

: Local data collector: Randi Eikeland

More information (external website)

NeuroCovid

: Originates from OUS

We contribute with patient recruitment/data collection.

Investigating the scope, symptoms, and signs of neurological manifestations of covid-19

Local data collector: Randi Eikeland

More information (external website)

BorrSci: Lyme borreliosis; a scientific approach to reduce diagnostic and therapeutic uncertainties (BorrSci)

An interdisciplinary and interregional project led by Sørlandet Hospital, consisting of 5 work packages;

: Epidemiology, clinical characteristics, laboratory findings in chronic Lyme disease

Comparison of 2 and 6 week doxycycline treatment for neuroborreliosis, a randomized, double-blinded, placebo-controlled, multi-center study

Establishment of a biobank for tick-borne diseases

Biomarkers in neuroborreliosis (immunology, genetics, MRI)

Dissemination of results and knowledge about neuroborreliosis.

: Number of planned PhDs: 5 (3 funded by SSHF)

: Financing: The regional health authorities via the Research Council of Norway.

Local PhD fellows

: Neurologist: Anne Marit Solheim. Supervisors: Unn Ljøstad and Åse Mygland

: Neuropsychologist: Silje Andreassen. Supervisors: Randi Eikeland ++

: Radiologist: Elisabeth Lindland. Supervisor: Åslaug Rudjord Lorentzen ++

More information (external website)

NeoPropp: NeoEhrlichiosis in patients with blood clots of unknown cause

A single study at SSHF that will investigate the prevalence of positive PCR for Neoerlichiosis in blood samples from patients hospitalized with stroke, DVT, and pulmonary embolism without another known cause.

: Neurological contact person: Benedicte Isefjær

: NOTES Tick-borne encephalitis TBE

: Departs from Telemark.

We contribute to patient recruitment/data collection.

  1. Description of acute illness in the cohort in Norway (2018 and 2019).
  2. What are the residual conditions? Examination with neuropsychological testing 24–36 months after infection.
  3. Following patients with regard to lasting immunity after infection. It is a project in collaboration with the Norwegian Institute of Public Health and is also in its early stages.

Local data collectors: Åslaug Rudjord Lorentzen and Randi Eikeland

Strength training to reduce headaches - a pilot study

Prospective pilot study at SSHF that will investigate whether strength training can reduce headaches in patients with chronic migraine and simultaneous tension headaches and muscular neck pain. Use of an app for follow-up.

Responsible: Magne Bøe and Kristine Forselv

: Financing: ?

: Who can participate?

. Have you received stem cell treatment abroad and do you have MS? You may be eligible to participate in the study.

If you are registered in the MS registry, a common link for study participation will be sent. If you have not received the invitation (sent out on November 6th).

Follow this link and join the study:Consent - SAFE MS We use cookies to improve your experience on our website. By continuing to use the website, you consent to our use of cookies. You can read more about our use of cookies and how to change your settings in our privacy policy: [https://www.safe.no/personvern](https://www.safe.no/personvern) I agree.

: Contact information:Stine Schikora-Rustad (stirus@sshf.no)

Lege Stine Schikora-Rustad
Stine Schikora-Rustad

: Project manager: Åslaug Rudjord Lorentzen

About the study:
The main goal of this study is to generate new knowledge about the safety and effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) as a treatment for multiple sclerosis (MS) as well as to investigate which groups benefit most from the treatment. This will be done by collecting information from several different registries and asking participants to answer a questionnaire.

PhD stipends are internally funded, and project support from the Norwegian MS Association.

What does the study involve:

All participants will, after signing the consent form, be asked to answer questions related to the stem cell treatment, as well as questions about quality of life and experiences.

There are no planned clinical controls or blood tests in the study, but we will retrieve data from various registries: Antibiotic use - retrieved from the medication registry, Hospital admissions - retrieved from the Norwegian patient registry, MS diagnosis, MRI findings, attack, EDSS, use of other MS medications after treatment - retrieved from the MS registry and/or patient records, Socioeconomic status - retrieved from Statistics Norway.

Four hypotheses have been formulated:

People with MS (pwMS) who have undergone AHSCT abroad are socioeconomically similar to pwMS who have not undergone AHSCT.

. AHSCT pmMS after treatment has the same degree of neurological outcomes, signs of disease activity, admissions to specialized neurological departments, and safety as matched non-AHSCT pmMS.

AHSCT pmMS has the same degree of depression, fatigue, anxiety, and quality of life as the matched non-AHSCT pmMS.

It is possible to find predictors for better outcomes after AHSCT.

 

Consent SAFE-MS_version1.2_200124.pdf

A multicenter, prospective, randomized, open-label study with blinded endpoint comparing treatment with cladribine versus rituximab in people with MS.

Originates from Oslo University Hospital/UiO.

We contribute with patient recruitment/data collection (recruitment completed).

Financing: NOR-MS was started before funding was in place, later open project support from HSØ and NFR.

Local chief examiner: Åslaug Rudjord Lorentzen

: Other local testers: Ingvild J Leiknes, Stine Schikora-Rustad

: Local study nurse: Siv Pettersen

: Follow link for more information:More information (external website)

A national study examining vaccine responses among people with MS by mapping both antibody formation (so-called humoral immune response) and activation of T-cells (so-called cellular immune response).

The study is being carried out in collaboration between Oslo University Hospital, Haukeland University Hospital, Akershus University Hospital, Southern Norway Hospital, the Norwegian MS Registry and Biobank, the Norwegian Institute of Public Health, and the MS Association.

The study started as a local project at OUS/SSHF (NOR-MS VAX), but quickly expanded into a national study.

The study is still recruiting patients (follow link below).

Local contributors: Åslaug Rudjord Lorentzen, Ingvild J Leiknes, Stine Schikora-Rustad.

: Follow link for more information:: OUH - Nevrovax (ous-research.no)

A multicenter, prospective, randomized, blinded study comparing treatment with rituximab versus ocrelizumab in people with MS.

Originates from Haukeland University Hospital/UiB.

We contribute with patient recruitment/data collection (recruitment completed).

Funding: KLINBEFORSK

: Local chief examiner: Åslaug Rudjord Lorentzen

: Other local testers: Ingvild J Leiknes

: Local study nurse: Siv Pettersen

: Follow link for more information:More information (external website)

A prospective, multi-center safety study to evaluate the long-term safety profile of LEMTRADA® (alemtuzumab) – treatment in patients with relapsing-remitting MS.

We contribute to patient recruitment/data collection.

: Financing: Sanofi

: Local tester: Åse Mygland

: Other local data collectors: Unn Ljøstad, Kristine JN Forselv

: Local study nurse: Siv Pettersen

Effect of intravenous immunoglobulins on painful sensory neuropathy evaluated by aggregated N-of-one trial

PhD project planned start within 2022: Evaluate the effect of IVIG on pain in sensory neuropathy using an N-of-one study design with individual randomized, double-blind and multiple crossover comparison of IVIG and placebo.

: Financing: Internally financed SSHF

PhD Candidate: Jon Marius Ørnes

: Supervisors: Unn Ljøstad and Åse Mygland

ParkVest: The Parkinson Study in Western Norway and Aust-Agder

Departs from Stavanger and Haukeland.

We contribute to patient recruitment/data collection.

A PhD candidate from SSHF is mapping the functionality and prevalence of motor and non-motor problems in a group of newly diagnosed Parkinson's disease patients.

: Financing?

PhD Candidate: Solgunn Ongre

: Guide: Karen Herlofson

More information (external website)

NoPark study: effect of Nicotinamide Riboside, a vitamin B3 analog, in patients with Parkinson's disease

Departs from Haukeland

We contribute to patient recruitment/data collection.

: Local tester: Karen Herlofson

More information (external website)

Tuberous Sclerosis: Online survey of patients with tuberous sclerosis in Norway in Dec-20 (treatment, 58 patients) and Dec-21 (follow-up, 48 patients). Ragnar Solhoff (SSHF) together with geneticist Ketil Heimdal, OUS. Supported by NK-SE with Ninan Benan (SSE) and NFTSC (patient association).


Stine Schikora-Rustad: SAFE-MS: Stem cell treatment abroad for Norwegian patients with multiple sclerosis.

Ivana Sapina: The Southern-Norway Post-Stroke Atrial Fibrillation Study.

: Solgunn OngreParkVest: Functionality and prevalence of motor and non-motor problems in newly diagnosed patients with Parkinson's disease.

: Anne Marit Solheim: BorrSci: Comparison of 2 and 6 week doxycycline treatment for neuroborreliosis, a randomized, double-blind, placebo-controlled, multi-center study.

Mary-Helen Søyland TWIST: Tenecteplase in Wake-up Ischemic Stroke Trial.

Jon Marius Ørnes: Effect of intravenous immunoglobulins on painful sensory neuropathy evaluated by aggregated N-of-one trial.

  • : Unn Ljøstad, PhD
  • Randi Eikeland, PhD
  • Karen Herlofson, PhD
  • : Pauline Do, neurologist
  • Ingvild Leiknes, neurologist
  • Åslaug Lorentzen, PhD
  • Åse Mygland, PhD
  • Harald Reiso, PhD
  • Stine Schikora-Rustad, PhD Candidate
  • Anne Marit Solheim, PhD Candidate
  • : Mary-Helen Søyland, PhD Candidate
  • Erik Thortveit, PhD
  • : Arnstein Tveiten, PhD
  • : Solgunn Ongre, PhD Candidate
  • Siv Pettersen, specialist nurse
  • Jon Marius Ørnes, PhD Candidate
  • Halvor Øygarden, PhD
  • Ivana Sapina, PhD Candidate

Editor: Unn Ljøstad,: Unn.Ljostad@sshf.no
: Board members:
Randi Eikeland
Erik Thortveit
Penelope Peterson
Last updated 05/14/2024